Beeline Medicines closes upsized Series A financing
US clinical-stage biotech Beeline Medicines has announced the closing of a $126.3 million Series A extension, bringing its total Series A financing round to $426.3 million.
The funding came from existing shareholders and investors, including Bain Capital, Canada Pension Plan Investment Board (CPP Investments), and Bristol Myers Squibb (NYSE: BMY), and included participation from certain members of the company’s management team. The proceeds from the upsized Series A will support the initiation of several clinical studies across the Company’s broad immunology portfolio, including planned pivotal development of its lead program, afimetoran, in lupus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze